Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Shenzhen Salubris Pharmaceuticals Co Ltd (Salubris) focuses on the research, development, manufacture and distribution of pharmaceutical products for the indication of orthopaedics, metabolism, oncology, cardiovascular and related diseases. The company's pipeline products include sacubitril allisartan calcium (S086) targets hypertension and chronic heart failure; allisartan isoproxilamlodipine besylate tablets and allisartan isoproxilindapamide sustained-release tablets for hypertension; enarodustat (SAL0951) treats renal anemia; SAL0104 for thrombosis; SAL007 targets chronic heart failure; and SAL003 for the treatment of hypercholesterolemia; SAL056, SAL001 and SAL023 targets osteoporosis; among others. It also develops interventional medical devices for cardiology, cerebrovascular, structural heart and peripheral vascular disease areas. Salubris is headquartered in Shenzhen, Guangdong, China.
Headquarters
China
Address
F37, Main Building,Chegong Temple, Lvgem Neo Square,No.6009 Shennan Boulvrd, Futian District, Shenzhen, Guangdong, 518040
Website
www.salubris.com
Telephone
86 755 83867888
No of Employees
4,087
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
002294 (SHE)
Revenue (2024)
$605.7M
8.5%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
8.3%
(2024 vs 2023)
Market Cap*
$8.3B
Net Profit Margin (2024)
XYZ
-0.1%
(2024 vs 2023)
* As of and is in US$
Shenzhen Salubris Pharmaceuticals Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | Salubri |
| Sacubitril Allisartan Calcium (S086): Hypertension and Chronic Heart Failure | Taijia |
| Hypertension: | Taiyi |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Regulatory Approval | In June, the company received approval from the NMPA for Fu Li An (Alisartan/Indapamide Extended-Release Tablets), China’s ARB + thiazide-like diuretic fixed-dose combination antihypertensive drug. |
| 2023 | Regulatory Approval | In July, the company secured an approval from the US FDA to conduct clinical trials for the drug SAL0119 in the US. |
| 2022 | Contracts/Agreements | In November, the company entered into a development agreement with Anlong Biopharmaceutical for cooperation in the research and development of RNAi drugs in the field of hypertension. |
Competitor Comparison
| Key Parameters | Shenzhen Salubris Pharmaceuticals Co Ltd | Shanghai Pharmaceuticals Holding Co Ltd | Huadong Medicine Co Ltd | Shanghai Fosun Pharmaceutical (Group) Co Ltd | Jiangsu Hengrui Pharmaceuticals Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Shenzhen | Shanghai | Hangzhou | Shanghai | Lianyungang |
| State/Province | Guangdong | Shanghai | Zhejiang | Shanghai | Jiangsu |
| No. of Employees | 4,087 | 49,608 | 18,265 | 40,603 | 20,602 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Ye Yuxiang | Chairman | Executive Board | 2022 | 51 |
| Yan Jie | Director; General Manager | Executive Board | 2018 | 53 |
| Yang Jianfeng | Secretary; Director | Executive Board | 2010 | 50 |
| Zhao Songping | Deputy General Manager | Senior Management | 2016 | 55 |
| Kong Yun | Director - Finance | Senior Management | 2021 | 52 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer